Company Overview of AdvanDx, Inc.
AdvanDx, Inc. provides molecular diagnostic tests for the identification of pathogens causing critical infections in hospitalized patients. The company specializes in the molecular testing of positive blood cultures that enable clinical microbiology labs to report pathogen identification results earlier than with conventional testing methods. It offers QuickFISH and PNA FISH tests for the identification of bacteria and yeast directly from positive blood cultures; and PNA Probes for ribosomal RNA sequences found in bacteria and fungi. The company also offers a starter system; accessories, such as microscope slides, cover slips, control slides, and PNA FISH kit components for performing QuickF...
Woburn, MA 01801
Founded in 2002
Key Executives for AdvanDx, Inc.
Chief Executive Officer and Director
Founder, President and Director
Founder, Vice President of Research & Development and Director
Compensation as of Fiscal Year 2015.
AdvanDx, Inc. Key Developments
OpGen, Inc., AdvanDx, Inc. - M&A Call
Jul 14 15
To discuss recent developments
AdvanDx, Inc. Receives FDA 510(K) Clearance for mecA XpressFISH
Nov 18 14
AdvanDx, Inc. announced that it has received U.S. Food and Drug Administration 510(k) clearance for its new mecA XpressFISH(TM) assay for the detection of methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA & MSSA) direct from blood culture samples. This phenotypic mRNA-targeting approach makes mecA XpressFISH unique in its mechanism of MRSA identification. mecA XpressFISH also provides results hours or days sooner than conventional laboratory methods which often require 48-72 hours. Drug resistance in MRSA is commonly conferred through expression of the bacterial mecA gene. mecA XpressFISH is a qualitative fluorescence in situ hybridization (FISH) assay that utilizes peptide nucleic acid (PNA) probes to bind and detect mecA messenger RNA (mRNA) sequences in blood cultures from patients infected with Staphylococcus aureus. Positive detection requires that the cells contain a functioning mecA gene.
AdvanDx, Inc. Announces Data from Thirteen Studies Highlighting AdvanDx's Infectious Disease Assays
May 16 14
AdvanDx, Inc. announced that data from thirteen studies will be presented at the General Meeting for the American Society for Microbiology beginning on May 17 in Boston, Massachusetts. Four of the studies will present data on mecA XpressFISH(TM) (FDA clearance pending), a novel method for the rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) from positive blood cultures. AdvanDx recently submitted its mecA XpressFISH assay to the U.S. Food and Drug Administration for 510(k) clearance. In addition, five studies will present data on the Company's QuickFISH products: Staphylococcus QuickFISH (FDA cleared; CE-IVD); Enterococcus QuickFISH (FDA cleared; CE-IVD); Gram-Negative QuickFISH (FDA cleared; CE-IVD); and QuickFISH Candida (CE-IVD).
Similar Private Companies By Industry
Recent Private Companies Transactions
July 14, 2015
February 27, 2015
Most Searched Private Companies
Sponsored Financial Commentaries